MGTX
VENTE TOTALE: 62 000 titres (~859 320,00 $ US)
- Insiders
- Forbes Alexandria
- Total bought
- —
- Total sold
- $859,320
- Last activity
- 2026-08-18
- Last synced
-
2026-08-25 17:08:49
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-26
MGTX presents a compelling event-driven catalyst — a strong earnings beat, FDA Breakthrough Therapy Designation, and positive Phase 1 data — but the underlying financial health is critically weak, with a current ratio…
The first sentence of the analysis written for MGTX on 2026-08-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 94.0% | 28.5% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -125.3% | -404.2% | -505.0% | -783.1% | -210.3% | |
| Ebitda Margin | -109.8% | -365.7% | -407.0% | -729.1% | -189.4% | |
| Operating Profit Margin | -130.2% | -493.4% | -977.8% | -730.9% | -193.0% | |
| Pretax Profit Margin | -140.3% | -444.1% | -599.5% | -814.2% | -211.0% | |
| Continuous Operations Profit Margin | -140.3% | -444.1% | -599.5% | -814.2% | -211.0% | |
| Net Profit Margin | -140.3% | -444.1% | -599.5% | -814.2% | -211.0% | |
| Bottom Line Profit Margin | -140.3% | -444.1% | -599.5% | -814.2% | -211.0% | |
| Current Ratio | 0.749 | 2.032 | 2.380 | 1.881 | 2.690 | |
| Quick Ratio | 0.749 | 2.026 | 2.380 | 1.881 | 2.690 | |
| Solvency Ratio | -0.406 | -0.668 | -0.373 | -0.604 | -0.532 | |
| Cash Ratio | 0.538 | 1.705 | 1.932 | 1.407 | 2.021 | |
| Price To Earnings Ratio | -5.599 | -2.873 | -4.711 | -2.272 | -13.189 | |
| Price To Earnings Growth Ratio | 0.170 | -0.068 | 0.098 | -0.038 | -0.510 | |
| Forward Price To Earnings Growth Ratio | 0.170 | -0.068 | 0.098 | -0.038 | -0.510 | |
| Price To Earnings Diluted Ratio | -5.599 | -2.873 | -4.711 | -2.272 | -13.189 | |
| Price To Earnings Diluted Growth Ratio | 0.170 | -0.068 | 0.098 | -0.038 | -0.510 | |
| Price To Book Ratio | -110.378 | 6.269 | 2.870 | 2.502 | 5.652 | |
| Price To Sales Ratio | 7.856 | 12.777 | 28.290 | 18.502 | 27.794 | |
| Price To Free Cash Flow Ratio | -12.741 | -3.885 | -3.159 | -2.495 | -15.938 | |
| Price To Operating Cash Flow Ratio | -13.793 | -4.069 | -3.763 | -4.030 | -99.513 | |
| Debt To Assets Ratio | 0.363 | 0.314 | 0.273 | 0.290 | 0.074 | |
| Debt To Equity Ratio | -15.309 | 1.250 | 0.646 | 0.784 | 0.128 | |
| Debt To Capital Ratio | 1.070 | 0.556 | 0.392 | 0.439 | 0.113 | |
| Long Term Debt To Capital Ratio | 1.132 | 0.519 | 0.343 | 0.376 | 0.000 | |
| Financial Leverage Ratio | -42.194 | 3.977 | 2.365 | 2.703 | 1.727 | |
| Working Capital Turnover Ratio | 5.096 | 0.429 | 0.170 | 0.170 | 0.226 | |
| Operating Cash Flow Ratio | -0.378 | -1.719 | -1.571 | -0.891 | -0.155 | |
| Operating Cash Flow Sales Ratio | -0.570 | -3.140 | -7.517 | -4.592 | -0.279 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.083 | 1.047 | 1.191 | 1.615 | 6.244 | |
| Debt Service Coverage Ratio | -2.426 | -9.169 | -4.307 | -23.467 | -247.917 | |
| Interest Coverage Ratio | -8.688 | -12.373 | -10.348 | -23.525 | -252.632 | |
| Short Term Operating Cash Flow Coverage Ratio | -1.881 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.523 | -1.232 | -1.180 | -0.792 | -0.444 | |
| Capital Expenditure Coverage Ratio | -12.117 | -21.089 | -5.223 | -1.626 | -0.191 | |
| Dividend Paid And Capex Coverage Ratio | -12.117 | -21.089 | -5.223 | -1.626 | -0.191 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -7.407 | -3.339 | -6.244 | -2.337 | -13.080 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 94.0% | ▲65.5% | ▲9.5% |
| Ebit Margin | -125.3% | ▲278.9% | ▲280.2% |
| Ebitda Margin | -109.8% | ▲255.8% | ▲250.4% |
| Operating Profit Margin | -130.2% | ▲363.2% | ▲374.9% |
| Pretax Profit Margin | -140.3% | ▲303.8% | ▲301.5% |
| Continuous Operations Profit Margin | -140.3% | ▲303.8% | ▲301.5% |
| Net Profit Margin | -140.3% | ▲303.8% | ▲301.5% |
| Bottom Line Profit Margin | -140.3% | ▲303.8% | ▲301.5% |
| Current Ratio | 0.749 | ▼-1.283 | ▼-1.197 |
| Quick Ratio | 0.749 | ▼-1.277 | ▼-1.196 |
| Solvency Ratio | -0.406 | ▲0.262 | ▲0.111 |
| Cash Ratio | 0.538 | ▼-1.167 | ▼-0.983 |
| Price To Earnings Ratio | -5.599 | ▼-2.726 | ▲0.130 |
| Price To Earnings Growth Ratio | 0.170 | ▲0.237 | ▲0.239 |
| Forward Price To Earnings Growth Ratio | 0.170 | ▲0.237 | ▲0.239 |
| Price To Earnings Diluted Ratio | -5.599 | ▼-2.726 | ▲0.130 |
| Price To Earnings Diluted Growth Ratio | 0.170 | ▲0.237 | ▲0.239 |
| Price To Book Ratio | -110.378 | ▼-116.647 | ▼-91.761 |
| Price To Sales Ratio | 7.856 | ▼-4.921 | ▼-11.188 |
| Price To Free Cash Flow Ratio | -12.741 | ▼-8.856 | ▼-5.098 |
| Price To Operating Cash Flow Ratio | -13.793 | ▼-9.723 | ▲11.241 |
| Debt To Assets Ratio | 0.363 | ▲0.049 | ▲0.100 |
| Debt To Equity Ratio | -15.309 | ▼-16.559 | ▼-12.809 |
| Debt To Capital Ratio | 1.070 | ▲0.514 | ▲0.556 |
| Long Term Debt To Capital Ratio | 1.132 | ▲0.613 | ▲0.658 |
| Financial Leverage Ratio | -42.194 | ▼-46.171 | ▼-35.910 |
| Working Capital Turnover Ratio | 5.096 | ▲4.668 | ▲3.878 |
| Operating Cash Flow Ratio | -0.378 | ▲1.341 | ▲0.564 |
| Operating Cash Flow Sales Ratio | -0.570 | ▲2.570 | ▲2.650 |
| Free Cash Flow Operating Cash Flow Ratio | 1.083 | ▲0.035 | ▼-1.153 |
| Debt Service Coverage Ratio | -2.426 | ▲6.743 | ▲55.031 |
| Interest Coverage Ratio | -8.688 | ▲3.685 | ▲52.825 |
| Short Term Operating Cash Flow Coverage Ratio | -1.881 | ▼-1.881 | ▼-1.505 |
| Operating Cash Flow Coverage Ratio | -0.523 | ▲0.710 | ▲0.312 |
| Capital Expenditure Coverage Ratio | -12.117 | ▲8.972 | ▼-4.068 |
| Dividend Paid And Capex Coverage Ratio | -12.117 | ▲8.972 | ▼-4.068 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -7.407 | ▼-4.068 | ▼-0.925 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $639.4M | $425.2M | $396.5M | $294.6M | $1.05B | |
| Enterprise value | $662.2M | $406.4M | $356.2M | $271.3M | $933.9M | |
| EV / Sales | 8.14x | 12.21x | 25.41x | 17.04x | 24.77x | |
| EV / Op. cash flow | -14.28x | -3.89x | -3.38x | -3.71x | -88.69x | |
| EV / Free cash flow | -13.20x | -3.71x | -2.84x | -2.30x | -14.21x | |
| EV / EBITDA | -7.41x | -3.34x | -6.24x | -2.34x | -13.08x | |
| Net debt / EBITDA | -0.26x | 0.15x | 0.71x | 0.20x | 1.60x | |
| Current ratio | 0.75x | 2.03x | 2.38x | 1.88x | 2.69x | |
| Income quality | 0.41x | 0.71x | 1.25x | 0.56x | 0.13x | |
| Graham net-net | -$2 | -$1 | -$1 | -$1 | $1 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 112.0% | 109.9% | 118.7% | 104.0% | 100.4% | |
| Working capital | -$30.8M | $62.7M | $92.5M | $72.3M | $115.1M | |
| Invested capital | $111.7M | $199.2M | $249.9M | $228.4M | $244.0M | |
| Return on assets | -46.7% | -54.8% | -25.7% | -40.7% | -24.9% | |
| Operating ROA | -41.2% | -55.1% | -42.5% | -36.5% | -21.3% | |
| Return on tangible assets | -46.8% | -55.0% | -25.8% | -41.0% | -25.1% | |
| Return on equity | 1971.4% | -217.9% | -60.8% | -110.1% | -42.9% | |
| Return on invested capital | -70.9% | -77.1% | -51.9% | -48.5% | -28.5% | |
| Return on capital employed | -86.9% | -78.6% | -52.8% | -49.3% | -28.9% | |
| Earnings yield | -17.9% | -34.8% | -21.2% | -44.0% | -7.6% | |
| Free cash flow yield | -7.8% | -25.7% | -31.7% | -40.1% | -6.3% | |
| Capex / Op. cash flow | -8.3% | -4.7% | -19.1% | -61.5% | -524.4% | |
| Capex / Depreciation | 30.1% | 39.1% | 147.0% | 522.6% | 701.3% | |
| Capex / Sales | 4.7% | 14.9% | 143.9% | 282.4% | 146.5% | |
| SG&A / Sales | 65.0% | 162.9% | 337.4% | 292.4% | 116.1% | |
| R&D / Sales | 159.3% | 359.0% | 740.4% | 538.5% | 176.9% | |
| Stock comp / Sales | 27.2% | 75.7% | 197.7% | 179.8% | 55.1% | |
| Intangibles / Total assets | 0.2% | 0.3% | 0.3% | 0.7% | 0.8% | |
| Days sales outstanding | 82d | 117d | 610d | 665d | 339d | |
| Days payables outstanding | 759d | 362d | 0d | 0d | 0d | |
| Operating cycle | 82d | 122d | 610d | 665d | 339d | |
| Cash conversion cycle | -677d | -239d | 610d | 665d | 339d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+50.4%EV / Sales ▼-33.4%EV / EBITDA ▼-121.8%EV / Op. cash flow ▼-10.395Earnings yield ▲+0.169
Profitability
Return on equity ▲+21.893Return on assets ▲+0.081Return on invested capital ▲+0.062Return on capital employed ▼-0.084Operating ROA ▲+0.138Income quality ▼-0.301Tax burden 0.000
Efficiency
Days sales outstanding ▼-34.563Days payables outstanding ▲+396.784Operating cycle ▼-40.469Cash conversion cycle ▼-437.254Capex / Sales ▼-0.102R&D / Sales ▼-1.998
Balance-sheet strength
Current ratio ▼-1.283Net debt / EBITDA ▼-0.410Working capital ▼-93529000.000Invested capital ▼-87491000.000Intangibles / Total assets ▼-0.001
Change over 5 years
Valuation
Market cap ▼-39.0%EV / Sales ▼-67.2%EV / EBITDA ▲+43.4%EV / Op. cash flow ▲+74.406Earnings yield ▼-0.103
Profitability
Return on equity ▲+20.143Return on assets ▼-0.219Return on invested capital ▼-0.424Return on capital employed ▼-0.581Operating ROA ▼-0.199Income quality ▲+0.274Tax burden 0.000
Efficiency
Days sales outstanding ▼-257.021Days payables outstanding n/aOperating cycle ▼-257.021Cash conversion cycle ▼-1015.660Capex / Sales ▼-1.418R&D / Sales ▼-0.176
Balance-sheet strength
Current ratio ▼-1.941Net debt / EBITDA ▼-1.851Working capital ▼-145909000.000Invested capital ▼-132259000.000Intangibles / Total assets ▼-0.006
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-13 MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates MeiraGTx Holdings PLC (MGTX) came out with quarterly earnings of $1.71 per share, beating the Zacks Consensus Estimate of a loss of $0.39 per share. This compares to a loss of $0.48 per share a year ago.
- 2026-08-13 MeiraGTx Reports Second Quarter 2026 Financial and Operational Results Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million Strengthened balance sheet with $100 million equity financing concurrent with the bota-vec acquisition Secured up to $400 million strategic investment from Oberland Capital, with up to $375 million in non-dilutive capital to support development and commercialization of AAV2-hAQP1 and bota-vec Anticipate submission of global regulatory filings for approval of bota-vec in 2026 and potential BLA filing for AAV2-hAQP1 in mid-2027 LONDON and NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the second quarter ended June 30, 2026, and provided a corporate update. “During the second quarter of 2026, we made tremendous progress towards transforming MeiraGTx into a commercial company,” said Alexandria Forbes, Ph.D.
- 2026-08-11 Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich''s Ataxia Graviton received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a novel capsule formulation of GV101 on August 7, 2026. FDA clearance marks a critical regulatory milestone in advancing this formulation of GV101, a capsule with improved PK and oral availability, into human trials for Friedreich''s ataxia (FA).
- 2026-08-06 MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) LONDON and NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company''s Board of Directors approved equity awards under the Company''s 2026 Employment Inducement Award Plan to a new employee. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-07-30 Some Potential Merit Within MeiraGTx Holdings MeiraGTx Holdings plc is positioned potentially for significant upside with late-stage gene therapy assets targeting large, high-unmet-need indications. AAV2-hAQP1 for radiation-induced xerostomia could address a $3.7B peak sales market with no direct competition; pivotal Phase 2 data expected 2Q27. Robust optionality from GAD for Parkinson''s, bota-vec for XLRP, milestone payments, and the innovative Riboswitch platform enhances MGTX''s valuation case.
- 2026-07-15 Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High? The mean of analysts'' price targets for MeiraGTx (MGTX) points to a 128.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 2026-07-12 What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near Stuart Naylor liquidated 27,659 shares for $409,000 on July 7, 2026, at a weighted average price of $14.80 per share. The transaction resulted in a 4% reduction of the insider''s total direct equity holdings in the company.
- 2026-07-08 MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last? MeiraGTx (MGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 2026-07-07 MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec) LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced that it has entered into an agreement with Oberland Capital Management LLC (Oberland Capital) for an investment of up to $400 million in the Company, including up to $375 million in non-dilutive capital for capped royalty payments on certain products and up to $25 million in equity.
- 2026-06-29 MeiraGTx: The Market Is Missing The Manufacturing Pivot MeiraGTx is evolving into a late-stage, manufacturing-enabled genetic medicine company with multiple near-term regulatory catalysts. MGTX''s robust manufacturing infrastructure and targeted therapies, such as Bota-vec and AAV2-hAQP1, position it for commercial inflection without mass-market commercialization burdens. Recent equity raise and anticipated milestone payments extend MGTX''s cash runway through 2H 2028, supporting execution of late-stage programs.